Characteristics of patients.

<p>Characteristics of patients.</p

Overall survival.

<p>Kaplan Meier estimates of overall survival evaluated from the date of lapatinib-based therapy initiation in 132 patients according to PFS >7 months (solid line) or PFS ≤7 months (dashed line). Median overall survival is 36 months (95% C.I. 9–21 months) and 15 months (19–53 months), respectively (p<0.001).</p

Multivariate analysis for Progression-free survival (PFS) and Overall Survival (OS) from the start of lapatinib-based therapy.

<p>Multivariate analysis for Progression-free survival (PFS) and Overall Survival (OS) from the start of lapatinib-based therapy.</p

Local-regional treatments.

<p>AST: adjuvant systemic therapy</p><p>Local-regional treatments.</p

Adjuvant systemic therapies.

<p>AST: adjuvant systemic therapy; CT: chemotherapy; HT: hormone therapy</p><p>Adjuvant systemic therapies.</p

Clinicopathologic characteristics and univariate analysis.

<p>LVI: lymphovascular invasion; HR: hormone receptor; AST: adjuvant systemic therapy; ER: estrogen receptor; PgR: progesteron receptor</p><p>*p-value according to Kruskal-Wallis, Chi square test or Fisher’s exact test, as appropriate</p><p>Clinicopathologic characteristics and univariate analysis.</p

A. Disease-free survival according to treatment group. Fig 1A shows Kaplan Meier’s disease-free survival curves according to treatment group. B. Disease-free survival according to stage. Fig 1B shows Kaplan Meier’s disease-free survival curves according to stage; the analysis was performed on 301 patients, since data on stage were missing for 2 patients.

<p>A. Disease-free survival according to treatment group. Fig 1A shows Kaplan Meier’s disease-free survival curves according to treatment group. B. Disease-free survival according to stage. Fig 1B shows Kaplan Meier’s disease-free survival curves according to stage; the analysis was performed on 301 patients, since data on stage were missing for 2 patients.</p